Last updated: May 26, 2026
CEREBYX is manufactured and supplied by multiple entities across the product chain, with different roles spanning drug substance (fosphenytoin) versus finished-dose drug product. This page inventories the supplier landscape for CEREBYX at the manufacturer and component level, with a focus on organizations that appear in official labeling/filing trails and common commercial sourcing patterns for complex sterile injectables.
Who supplies CEREBYX (fosphenytoin) to pharmacies and hospitals?
Commercial supply is anchored to the FDA-approved marketing authorization holder(s) and the licensed drug product manufacturer(s) responsible for sterile injectable release. For CEREBYX, the supply chain is typically structured as:
- Marketing authorization holder (label holder)
- Sterile drug product manufacturer (finished dose, aseptic processing, labeling, packaging)
- Drug substance manufacturer (fosphenytoin)
- Contract manufacturers for sterile fill-finish, batch release testing, and secondary packaging
What label-holder entities typically control CEREBYX supply?
CEREBYX is marketed in the U.S. as a specialized injectable antiepileptic under a specific FDA label holder. The label holder controls supply contracting and is the entity that appears on the prescribing information for “Manufactured for” and similar statements.
Which drug product manufacturers handle aseptic sterile fill-finish for CEREBYX?
CEREBYX is supplied as a sterile injectable, requiring:
- aseptic processing and sterile filtration
- controlled temperature and handling
- terminal sterility assurance strategy aligned with the approved manufacturing process
- container closure integrity assurance for the vial system
In practical terms, finished-dose manufacture for this category is commonly performed by licensed sterile injectables CDMOs under contract to the label holder.
Which companies supply the phosphenytoin drug substance used in CEREBYX?
Fosphenytoin (the prodrug of phenytoin) is the drug substance. Drug substance suppliers are typically:
- specialized API manufacturers with controlled synthesis and impurity profiles
- internal API plants owned by the label holder, or third-party API vendors
- companies capable of GMP commercial batches with validated impurity and residual solvent limits
Drug substance supply chain bottlenecks for fosphenytoin
Key procurement constraints for fosphenytoin include:
- tight impurity specifications relative to phenytoin conversion
- validated hydrolysis and conversion controls during manufacturing
- scalable crystallization and drying processes that preserve polymorph and particle properties
What is the difference between “CEREBYX suppliers” and “CDMO suppliers” for sterile injectables?
In procurement and contracting, “supplier” often collapses multiple roles. For CEREBYX, the practical distinctions are:
Drug product supplier (finished injectable)
- Owns the approved finished-dose manufacturing and release
- Controls vial fill volume, concentration, aseptic process, and labeling configuration
Drug substance supplier (API)
- Produces phosphenytoin under GMP
- Supplies API to the finished-dose manufacturer via supply agreements
Component suppliers
- vial/stopper suppliers (glass and elastomer systems compatible with sterile pharmaceuticals)
- secondary packaging suppliers (cartons, labels)
- testing reagents and analytical standards suppliers (used in QC release)
How do hospitals typically source CEREBYX and validate its supplier chain?
Hospitals source CEREBYX through:
- GPO channels and direct distributor contracts
- wholesalers that manage lot-level traceability
Validation practices commonly include:
- checking NDC, lot number, and expiration date at receipt
- verifying temperature excursions and shipping condition
- retaining Certificates of Analysis and reviewing CoA coverage for each lot
What suppliers are involved in packaging and vial/stopper systems for CEREBYX?
Sterile injectable vials are defined by:
- glass type (typically borosilicate for injectables)
- stopper and closure material compatibility
- container closure integrity performance
- labeling and carton specifications aligned with the U.S. package design
Stopper and vial suppliers are usually specialized container closure manufacturers used across multiple injectable lines. These companies provide validated component specs and change-control documentation to the drug product manufacturer.
Supplier risk: What can disrupt CEREBYX availability?
Availability disruptions for sterile injectables usually come from:
- upstream API delays (fosphenytoin synthesis capacity)
- sterile fill-finish plant downtime
- constrained availability of vial/stopper components with validated compatibility
- QC testing reagent shortages or instrument calibration backlogs
- recalls tied to container closure integrity or particulate issues
A supplier strategy that reduces risk usually includes:
- at least one alternate finished-dose manufacturer
- dual-source API where approved/validated
- backup container closure suppliers with validated change control
CEREBYX supplier map (commercial roles and where suppliers sit in the chain)
| Supply-chain node |
Role |
Typical supplier type |
What to request for due diligence |
| Marketing authorization holder |
Controls label and supply agreements |
Brand owner |
Forecasted allocation, approved manufacturing sites list, change control policy |
| Sterile drug product manufacturer |
Produces and releases sterile CEREBYX |
Contract sterile injectables manufacturer and/or internal plant |
Batch record controls, aseptic process validation, sterile assurance strategy |
| Drug substance manufacturer |
Makes fosphenytoin API |
API GMP manufacturer |
DMF status, impurity profile specs, residual solvent compliance |
| Container closure system (vial/stopper) |
Delivers validated container components |
Container closure supplier |
Extractables/leachables, compatibility studies, CCIT results |
| QC release testing |
Performs potency, impurity, sterility/bioburden tests |
In-house or contracted lab |
Method validation package and lot-level CoA process |
Key takeaways
- CEREBYX supply is split between the label-controlled sterile drug product manufacturer and fosphenytoin API producers.
- Component suppliers primarily include validated vial and stopper manufacturers that meet compatibility and container closure integrity requirements for sterile injectables.
- Real supply risk concentrates in sterile fill-finish capacity and fosphenytoin API availability, with additional risk from validated container closure component shortages.
FAQs
-
How can distributors verify the lot-level supplier chain for CEREBYX?
By matching NDC and lot number to received documentation including lot-specific CoA, traceability records, and manufacturer of record documentation on the unit pack.
-
Do CEREBYX supply contracts include alternative sterile fill-finish sites?
Many do, but procurement outcomes depend on whether alternate sites have been qualified for the approved process and whether inventory is allocated accordingly.
-
What documentation should be reviewed to confirm the source of fosphenytoin API for CEREBYX?
Lot-specific CoA for fosphenytoin API and traceability documentation tying the API lot to the finished-dose batch record.
-
Can container closure changes affect CEREBYX availability or approval status?
Yes, validated extractables/leachables and CCIT requirements can slow substitutions if change control cannot be supported with comparability data.
-
What are the most common causes of intermittent shortages for sterile antiepileptic injectables like CEREBYX?
Sterile manufacturing disruptions, API capacity constraints for the prodrug intermediate, and container closure component lead-time constraints.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations.
- U.S. Food and Drug Administration. Drug Approval Packages and Labeling (Prescribing Information for CEREBYX).
- FDA. Application and approval records for CEREBYX (NDA labeling and manufacturing information).
